Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy

Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model

(2013) Larry Zeitlin et al.   mAbs

Properties of mouse and human IgG receptors and their contribution to disease models

(2012) P. Bruhns   BLOOD

A review of cost–effectiveness of palivizumab for respiratory syncytial virus

(2012) Julia M Hussman et al.   Expert Review of Pharmacoeconomics & Outcomes Research

The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence

(2012) J.M. Hussman et al.   JOURNAL OF MEDICAL ECONOMICS

Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective

(2012) Parthiv J. Mahadevia et al.   JOURNAL OF MEDICAL ECONOMICS

Emerging antibody products and Nicotiana manufacturing

(2011) Kevin J. Whaley et al.   Human vaccines & immunotherapeutics

Clinical development of plant-produced recombinant pharmaceuticals: Vaccines, antibodies and beyond

(2011) Vidadi Yusibov et al.   Human vaccines & immunotherapeutics

Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus Infection in High-risk Children, Based on Long-term Epidemiologic Data From Austria

(2011) Bernhard Resch et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant

(2011) L. Zeitlin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glycan labeling strategies and their use in identification and quantification

(2010) L. R. Ruhaak et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma

(2010) M. Bendandi et al.   ANNALS OF ONCOLOGY

Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis

(2010) E. Rietveld et al.   ARCHIVES OF DISEASE IN CHILDHOOD

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children

(2010) Eric A.F. Simões et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Fc-Glycosylation Influences Fc  Receptor Binding and Cell-Mediated Anti-HIV Activity of Monoclonal Antibody 2G12

(2010) D. N. Forthal et al.   JOURNAL OF IMMUNOLOGY

Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion

(2010) K. Huang et al.   JOURNAL OF VIROLOGY

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

(2010) Harish Nair et al.   LANCET

The cost effectiveness of palivizumab: a systematic review of the evidence

(2010) Kelly A. Smart et al.   JOURNAL OF MEDICAL ECONOMICS

Changing costs and the impact on RSV prophylaxis

(2010) Kelly A. Smart et al.   JOURNAL OF MEDICAL ECONOMICS

Aspects méthodologiques de l’évaluation économique du médicament en pédiatrie : exemple de la prophylaxie de l’infection à VRS en France

(2008) J.-M. Hascoet et al.   ARCHIVES DE PEDIATRIE

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis

(2008) Krista L. Lanctôt et al.   CURRENT MEDICAL RESEARCH AND OPINION

Antibodies against viruses: passive and active immunization

(2008) Mansun Law et al.   CURRENT OPINION IN IMMUNOLOGY

Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure

(2008) Richard Strasser et al.   PLANT BIOTECHNOLOGY JOURNAL

Glycosylation of Recombinant Antibody Therapeutics

(2005) Royston Jefferis   BIOTECHNOLOGY PROGRESS